In the final days of 2024, three pharmaceutical giants sued the federal government. In their joint lawsuit, Amgen, Eli Lilly ...

The industry could see payment, workforce and insurance coverage changes depending on how the Trump administration weighs in ...

With 2025 underway, the AFS Health Care team highlights some of the most pressing legal issues facing the health care industry this year.

The 340B requirement has long been a bone of contention ... Last year, for example, a federal appeals court sided with Sanofi, AstraZeneca, and Novo Nordisk in a dispute claiming that recipients ...

Eli Lilly, Bristol Myers Squibb, Sanofi and Novartis are seeking to block a major hospital trade group from intervening in ...

But profits need to come from somewhere. By expanding the federal 340B prescription drug program, the bill increases drug costs for Utah residents and businesses while benefitting the major chain ...

The FDA granted orphan designation to Sanofi (SNY) US Services’ rilzabrutinib as a treatment of autoimmune hemolytic anemia, according to a post to the agency’s website. Published first on ...

In this article, we are going to take a look at where Sanofi (NASDAQ:SNY) stands against the other pharmaceutical stocks. Almost no other industry goes as far as the phrase "defensive" as the ...

Bernstein analyst Florent Cespedes maintained a Buy rating on Sanofi (SNYNF – Research Report) today and set a price target of €114.00. The company’s shares closed last Tuesday at $108.11.

Sanofi Consumer Healthcare India Q4 Results 2025:Sanofi Consumer Healthcare India declared their Q4 results on 20 Feb, 2025. The topline decreased by 20.53% year-over-year (YoY), with profit ...